FBTCX
Fidelity Advisor Biotechnology Fund
Fidelity Advisor Series VII
Expense ratio1
1.71%
Net assets2
$1.87B
Holdings2
87
Category
US Equity
2025 return3
35.77%

Investment objective & strategy

As of Sept. 24, 2025 · prospectus

Objective. Fidelity Advisor Biotechnology Fund seeks capital appreciation.

Strategy. Normally investing primarily in common stocks. Normally investing at least 80% of assets in securities of companies principally engaged in the research, development, manufacture, and distribution of various biotechnological products, services, and processes, and companies that benefit significantly from scientific and technological advances in biotechnology. These companies may include, for example, companies engaged in the research, development, manufacturing, or marketing of products based in whole or in part on genetic analysis and genetic engineering. Fidelity may consider a company to be principally engaged in the designated business activity or activities based on: (i) the level of a company's assets, income, sales, or profits that are committed to, derived from, or related to the designated business activity or activities, or (ii) … Normally investing primarily in common stocks. Normally investing at least 80% of assets in securities of companies principally engaged in the research, development, manufacture, and distribution of various biotechnological products, services, and processes, and companies that benefit significantly from scientific and technological advances in biotechnology. These companies may include, for example, companies engaged in the research, development, manufacturing, or marketing of products based in whole or in part on genetic analysis and genetic engineering. Fidelity may consider a company to be principally engaged in the designated business activity or activities based on: (i) the level of a company's assets, income, sales, or profits that are committed to, derived from, or related to the designated business activity or activities, or (ii) whether a third party has given the company an industry or sector classification consistent with the designated business activity or activities. Whether a company is principally engaged in the designated business activity or activities can be determined under any of these factors. Effective December 11, 2025, derivative instruments that provide investment exposure to the investments above or exposure to one or more market risk factors associated with such investments are included in the fund's 80% policy, consistent with the fund's investment policies and limitations with respect to investments in derivatives. Investing in domestic and foreign issuers. Using fundamental analysis of factors such as each issuer's financial condition and industry position, as well as market and economic conditions, to select investments.

Top holdings

As of Jan. 31, 2026 · N-PORT
SecurityTickerValue% of fund
ABBVIE INC $309.89M 16.61%
GILEAD SCIENCES INC $122.66M 6.57%
ALNYLAM PHARMACEUTICALS INC $93.71M 5.02%
Ascendis Pharma A/S $83.80M 4.49%
COGENT BIOSCIENCES INC $71.40M 3.83%
ARGENX SE SPONSORED ADR $68.08M 3.65%
Fidelity Securities Lending Cash Central Fund $66.94M 3.59%
INSMED INC $64.68M 3.47%
VIRIDIAN THERAPEUTICS INC $58.82M 3.15%
BIOGEN INC $52.91M 2.84%
View all holdings →

Allocation by sector

As of January 31, 2026 · N-PORT
View portfolio breakdown →

Portfolio moves

Oct 31, 2025 → Jan 31, 2026
Opened
15
Exited
8
Increased
14
Decreased
27
Unchanged
31

How many positions this fund opened, exited, grew, trimmed, or left unchanged between its two most recent N-PORT snapshots — net changes between point-in-time reports, not a trade log.

View portfolio moves →

Similar funds

Funds whose portfolios most overlap this one, by weight
FundOverlapNet exp.
Select Biotechnology Portfolio · FBIOX 56% 0.63%
Select Health Care Portfolio · FSPHX, FHCQX, FHCRX, FHCLX, FHCNX, FHCPX 40% 0.55%
Biotechnology Fund · RYOIX, RYOAX, RYBOX, RYCFX 38% 1.40%
View all similar funds →

Advisers

As of July 31, 2025 · N-CEN
FirmRole
FMR Investment Management (UK) Limited Sub-adviser
Fidelity Management & Research (Japan) Limited Sub-adviser
Fidelity Management & Research (Hong Kong) Limited Sub-adviser
Fidelity Management & Research Company LLC Adviser

Footnotes

  1. Expense ratio as of September 24, 2025, from the fund's prospectus.
  2. Net assets and holdings count as of January 31, 2026, from the fund's N-PORT filing.
  3. Total return for calendar year 2025, before tax and after fund expenses. Computed by compounding the twelve monthly total returns the fund reported in its SEC N-PORT filings for 2025 (the latest prospectus does not yet chart this year).

Machine-readable: JSON · Markdown. Programmatic access via the agent surface.